KYTX: Miv-cel shows unprecedented efficacy in SPS, with regulatory and commercial milestones set for 2027
Transformative clinical results for miv-cel in SPS and MG drive regulatory progress, with a rolling BLA for SPS on track for Q4 completion and launch readiness in 2027. Manufacturing innovations and focused commercialization strategies support expansion into larger neuroimmunology indications.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.